There are 717 resources available
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
Introduction
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience
Presenter: John Wen-Cheng Chang
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC
Presenter: Hiroshi Tanaka
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
KRAS-mutant NSCLC treatment advances on the horizon
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Closing
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast